XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.22.1

Inventory | 3 Months Ended
--- | ---
Mar. 31, 2022
Inventory Disclosure [Abstract] |
Inventory | (4) Inventory The Company capitalizes its purchases of saleable inventory of VASCEPA from suppliers that have been qualified by the U.S. FDA. Inventories as of March 31, 2022 and December 31, 2021 consist of the following:
In thousands |  | March 31, 2022 |  |  | December 31, 2021 |
Raw materials |  | $ | 123,318 |  |  | $ | 107,695 |
Work in process |  |  | 56,217 |  |  |  | 41,965 |
Finished goods |  |  | 229,335 |  |  |  | 206,270 |
Total inventory |  | $ | 408,870 |  |  | $ | 355,930 |
As of March 31, 2022 and December 31, 2021, the Company had $141.1 million and $121.3 million of Long-term inventory, respectively, as consumption is expected beyond the Company's normal operating cycle.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -URI http://asc.fasb.org/topic&trid=2126998 + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration